Zydus Cadila

Cadlia Healthcare Ltd on Monday said group firm Zydus Pharmaceuticals (USA) Inc has received final approval from the US health regulator to market its generic version of Roflumilast tablets in the strength of 500 mcg indicated to reduce the risk of

Pharmaceutical company Zydus on Wednesday announced that it has started the supplies of its COVID-19 vaccine ZyCoV-D to the Government of India against their order from its newly commissioned state-of-the-art.

Drug firm Zydus Cadila on Friday said it has received approval from the US health regulator to market generic drug Cariprazine capsules, which are used in the treatment of schizophrenia.

Zydus Cadila's Covid vaccine ZyCoV-D will initially be used in 7 states, including Maharashtra, Tamil Nadu, UP and Bengal, which have been recommended to identify the districts with a high number of people who have not received a single dose yet.

India-based pharma giant, Zydus Cadila received final approval from US Food and Drug Administration (FDA) for Glycopyrrolate injection that is used before surgery to decrease the volume of secretions from the mouth, lungs and stomach.

The indigenously developed world's first DNA-based needle-free COVID-19 vaccine ZyCoV-D received emergency use authorisation from the drug regulator on August 20.

Zydus Cadila's ZyCov-D is the first vaccine cleared by India's drug regulator for inoculation of those aged 12 years and above

As many as 60 lakh doses of Zydus Cadila's three-dose COVID-19 vaccine ZyCoV-D are ready after production, said government sources.

The government today said Zydus Cadila's indigenously-developed needle-free Covid vaccine ZyCoV-D will be introduced in the nationwide vaccination drive very shortly and will be differentially priced than the jabs being used currently.

Preparations are on to make Zydus Cadila's COVID-19 DNA vaccine available to people and although the price is a "clear issue", a decision will be taken soon to make it a part of the country's vaccination programme, the government said on Thursday.

The discussion on the pricing of Zydus Cadila's COVID-19 vaccine ZyCoV-D is underway, said Dr VK Paul, Member (Health) NITI Aayog on Tuesday.

The permission has been given to Biological E after the recommendation from the Subject Expert Committee.

Details for the vaccination of children between 12 and 17 years of age, including prioritising those with comorbidities, will be made public before the Zydus Cadila vaccine is rolled out in October, Dr NK Arora said

Zydus Cadila's Covid vaccine, ZyCoV-D, has received approval for emergency use authorization from the Drug Controller General of India

There will be more clarity on the prices of COVID-19 vaccine ZyCOV-D by next week, Zydus Group Managing Director Dr Sharvil Patel said today.

Cadlia Healthcare Ltd on Monday said group firm Zydus Pharmaceuticals (USA) Inc has received final approval from the US health regulator to market its generic version of Roflumilast tablets in the strength of 500 mcg indicated to reduce the risk of

Pharmaceutical company Zydus on Wednesday announced that it has started the supplies of its COVID-19 vaccine ZyCoV-D to the Government of India against their order from its newly commissioned state-of-the-art.

Drug firm Zydus Cadila on Friday said it has received approval from the US health regulator to market generic drug Cariprazine capsules, which are used in the treatment of schizophrenia.

Zydus Cadila's Covid vaccine ZyCoV-D will initially be used in 7 states, including Maharashtra, Tamil Nadu, UP and Bengal, which have been recommended to identify the districts with a high number of people who have not received a single dose yet.

India-based pharma giant, Zydus Cadila received final approval from US Food and Drug Administration (FDA) for Glycopyrrolate injection that is used before surgery to decrease the volume of secretions from the mouth, lungs and stomach.

The indigenously developed world's first DNA-based needle-free COVID-19 vaccine ZyCoV-D received emergency use authorisation from the drug regulator on August 20.

Zydus Cadila's ZyCov-D is the first vaccine cleared by India's drug regulator for inoculation of those aged 12 years and above

As many as 60 lakh doses of Zydus Cadila's three-dose COVID-19 vaccine ZyCoV-D are ready after production, said government sources.

The government today said Zydus Cadila's indigenously-developed needle-free Covid vaccine ZyCoV-D will be introduced in the nationwide vaccination drive very shortly and will be differentially priced than the jabs being used currently.

Preparations are on to make Zydus Cadila's COVID-19 DNA vaccine available to people and although the price is a "clear issue", a decision will be taken soon to make it a part of the country's vaccination programme, the government said on Thursday.

The discussion on the pricing of Zydus Cadila's COVID-19 vaccine ZyCoV-D is underway, said Dr VK Paul, Member (Health) NITI Aayog on Tuesday.

The permission has been given to Biological E after the recommendation from the Subject Expert Committee.

Details for the vaccination of children between 12 and 17 years of age, including prioritising those with comorbidities, will be made public before the Zydus Cadila vaccine is rolled out in October, Dr NK Arora said

Zydus Cadila's Covid vaccine, ZyCoV-D, has received approval for emergency use authorization from the Drug Controller General of India

There will be more clarity on the prices of COVID-19 vaccine ZyCOV-D by next week, Zydus Group Managing Director Dr Sharvil Patel said today.